Share on StockTwits
 

Stock analysts at Imperial Capital started coverage on shares of Nutraceutical International Corp. (NASDAQ:NUTR) in a report issued on Wednesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $32.00 price target on the stock. Imperial Capital’s target price would suggest a potential upside of 22.51% from the company’s current price.

The analysts wrote, “We are initiating coverage of Nutraceutical International Corporation (NUTR) with an Outperform rating and one-year price target of $32 per share, roughly 23% above the recent share price. NURT is an integrated manufacturer, marketer, distributor, and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. We believe NUTR offers investors attractive exposure to the broader health and wellness category at a reasonable price.”

Nutraceutical International Corp. (NASDAQ:NUTR) traded up 0.73% during mid-day trading on Wednesday, hitting $26.12. The stock had a trading volume of 21,706 shares. Nutraceutical International Corp. has a 52-week low of $15.61 and a 52-week high of $27.54. The stock’s 50-day moving average is $25.66 and its 200-day moving average is $24.56. The company has a market cap of $257.4 million and a P/E ratio of 14.49.

Nutraceutical International Corp. (NASDAQ:NUTR) last released its earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter. The company had revenue of $51.55 million for the quarter, compared to the consensus estimate of $49.74 million.

Nutraceutical International Corporation (NASDAQ:NUTR) is an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold to and through domestic health and natural food stores.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.